| Drug Name |
Dacomitinib |
| Drug ID |
BADD_D02545 |
| Description |
Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains.[A40009]
Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018.[L4810] Some evidence in the literature suggests the therapeutic potential of dacomitinib in the epithelial ovarian cancer model[A39624], although further investigations are needed. |
| Indications and Usage |
Dacomitinib is indicated as the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as verified by an FDA-approved test.[L4812]
Lung cancer is the leading cause of cancer death and NSCLC accounts for 85% of lung cancer cases. From the cases of NSCLC, approximately 75% of the patients present a late diagnosis with metastatic and advanced disease which produces a survival rate of 5%. The presence of a mutation in EGFR accounts for more than the 60% of the NSCLC cases and the overexpression of EGFR is associated with frequent lymph node metastasis and poor chemosensitivity.[A40018, A19201] |
| Marketing Status |
approved; investigational |
| ATC Code |
L01EB07 |
| DrugBank ID |
DB11963
|
| KEGG ID |
D09883; D10514
|
| MeSH ID |
C525726
|
| PubChem ID |
11511120
|
| TTD Drug ID |
D06XXH
|
| NDC Product Code |
63539-197; 0069-0197; 0069-2299; 0069-1198 |
| UNII |
5092U85G58
|
| Synonyms |
dacomitinib | Vizimpro | N-(4-(3-chloro-4-fluoroanilino)-7-methoxy-6-quinazolinyl)-4-(1-piperidinyl)-2-butenamide | PF 00299804 | PF00299804 | PF-00299804 |
